SEARCH:   Advanced

Blood, 15 August 2004, Vol. 104, No. 4, pp. 1201-1203. Prepublished online as a Blood First Edition Paper on March 23, 2004; DOI 10.1182/blood-2003-08-2800. This Article Full Text (PDF) All Versions of this Article: 2003-08-2800v1 104/4/1201    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sodani, P. Articles by Lucarelli, G. Search for Related Content PubMed PubMed Citation Articles by Sodani, P. Articles by Lucarelli, G. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 14, 2003 Accepted February 25, 2004 A new approach for bone marrow transplantation in class 3 thalassemic patients aged less than 17 years Pietro Sodani, Djavid Gaziev, Paola Polchi, Buret Erer, Claudio Giardini, Emanuele Angelucci, Donatella Baronciani, Marco Andreani, Marisa Manna, Sonia Nesci, Barbarella Lucarelli, Reginald A Clift*, and Guido Lucarelli Azienda Ospedale S. Salvatore di Pesaro, U.O. Ematologia e Centro Trapianto di Midollo Osseo di Muraglia, Pesaro, Italy Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Mediterranean Institute of Hematology, Rome, Italy * Corresponding author; email: rclift{at}fhcrc.org. When prepared for transplantation with busulfan (BU) 14 mg/kg and cyclophosphamide (CY) 120 - 160 mg/kg, thalassemic patients in risk class 3, aged younger than 17 years, transplanted from HLA identical donors, had a 30% incidence of transplant rejection with recurrence of thalassemia. This, relatively poor, outcome was ascribed to insufficient immune suppression or to inadequate eradication of the thalassemic marrow, or both. In an attempt to enhance both immune suppression and eradication of the thalassemic clones, hydroxyurea, azathioprine and fludarabine were added to the BU and CY. This regimen, called Protocol 26, was applied to 33 consecutive class 3 thalassemic patients aged less than 17 years and was well tolerated with 93% survival. The incidence of recurrent thalassemia after the transplant decreased from 30 to 8 percent. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. A. Cahill, D. Wenkert, S. A. Perlman, A. Steele, S. P. Coburn, W. H. McAlister, S. Mumm, and M. P. Whyte Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2923 - 2930. [Abstract] [Full Text] [PDF] F. Locatelli Reduced-Intensity Regimens in Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathies Hematology, January 1, 2006; 2006(1): 398 - 401. [Abstract] [Full Text] [PDF] D. Rund and E. Rachmilewitz {beta}-Thalassemia N. Engl. J. Med., September 15, 2005; 353(11): 1135 - 1146. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020